Neurocrine Biosciences Inc NB3-FF:Frankfurt Stock Exchange

RT Quote | Exchange | EUR
Last | 03/05/21 CET
77.14quote price arrow down-0.92 (-1.18%)
Volume
30
52 week range
67.66 - 120.00

...

Loading . . .

KEY STATS

  • Open76.94
  • Day High78.38
  • Day Low76.94
  • Prev Close77.14
  • 52 Week High120.00
  • 52 Week High Date07/09/20
  • 52 Week Low67.66
  • 52 Week Low Date03/19/20
  • Market Cap10,239.18M
  • Shares Out93.5M
  • 10 Day Average Volume81.36
  • Dividend-
  • Dividend Yield-
  • Beta
  • 1 Year % Change-10.03

RATIOS/PROFITABILITY

  • EPS (TTM)3.40
  • P/E (TTM)22.69
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Neurocrine Biosciences Inc News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2)...
William Rastetter Ph.D.
Chairman
Kevin Gorman Ph.D.
Chief Executive Officer
Matthew Abernethy CPA
Chief Financial Officer
Address
12780 El Camino Real
San Diego, CA
92130-2042
United States